[go: up one dir, main page]

WO2001068705A3 - Il-17 receptor like molecules and uses thereof - Google Patents

Il-17 receptor like molecules and uses thereof Download PDF

Info

Publication number
WO2001068705A3
WO2001068705A3 PCT/US2001/008688 US0108688W WO0168705A3 WO 2001068705 A3 WO2001068705 A3 WO 2001068705A3 US 0108688 W US0108688 W US 0108688W WO 0168705 A3 WO0168705 A3 WO 0168705A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
polypeptides
methods
molecules
amelioration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/008688
Other languages
French (fr)
Other versions
WO2001068705A2 (en
Inventor
Shuqian Jing
Eugene Medlock
Richard Yeh
Scott M Silbiger
Gary S Elliot
Hung Q Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to CA002401273A priority Critical patent/CA2401273A1/en
Priority to JP2001567795A priority patent/JP2003527117A/en
Priority to AU2001259029A priority patent/AU2001259029B2/en
Priority to MXPA02009024A priority patent/MXPA02009024A/en
Priority to EP01932510A priority patent/EP1265924A2/en
Priority to AU5902901A priority patent/AU5902901A/en
Publication of WO2001068705A2 publication Critical patent/WO2001068705A2/en
Publication of WO2001068705A3 publication Critical patent/WO2001068705A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Novel IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.
PCT/US2001/008688 2000-03-16 2001-03-16 Il-17 receptor like molecules and uses thereof Ceased WO2001068705A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002401273A CA2401273A1 (en) 2000-03-16 2001-03-16 Il-17 receptor like molecules and uses thereof
JP2001567795A JP2003527117A (en) 2000-03-16 2001-03-16 IL-17 receptor-like molecules and uses thereof
AU2001259029A AU2001259029B2 (en) 2000-03-16 2001-03-16 Il-17 receptor like molecules and uses thereof
MXPA02009024A MXPA02009024A (en) 2000-03-16 2001-03-16 Il 17 receptor like molecules and uses thereof.
EP01932510A EP1265924A2 (en) 2000-03-16 2001-03-16 Il-17 receptor like molecules and uses thereof
AU5902901A AU5902901A (en) 2000-03-16 2001-03-16 Il-17 receptor like molecules and uses thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US18992300P 2000-03-16 2000-03-16
US60/189,923 2000-03-16
US20420800P 2000-05-12 2000-05-12
US60/204,208 2000-05-12
US72323200A 2000-11-27 2000-11-27
US09/723,232 2000-11-27
US26615901P 2001-02-02 2001-02-02
US60/266,159 2001-02-02

Publications (2)

Publication Number Publication Date
WO2001068705A2 WO2001068705A2 (en) 2001-09-20
WO2001068705A3 true WO2001068705A3 (en) 2002-07-18

Family

ID=27497823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/008688 Ceased WO2001068705A2 (en) 2000-03-16 2001-03-16 Il-17 receptor like molecules and uses thereof

Country Status (8)

Country Link
EP (1) EP1265924A2 (en)
JP (1) JP2003527117A (en)
AR (1) AR030554A1 (en)
AU (2) AU2001259029B2 (en)
CA (1) CA2401273A1 (en)
MX (1) MXPA02009024A (en)
TW (1) TWI322154B (en)
WO (1) WO2001068705A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9475873B2 (en) 2009-05-05 2016-10-25 Novimmune Sa Nucleic acids encoding anti-IL-17F antibodies and methods of use thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060127A2 (en) 1998-05-15 1999-11-25 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP1897945B1 (en) * 1999-12-23 2012-01-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2007202616B2 (en) * 2000-06-22 2011-08-18 Amgen Inc. IL-17 Like Molecules and Uses Thereof
AU2002246746B2 (en) * 2000-10-18 2007-05-31 Kirin-Amgen, Inc. Methods for treating rheumatoid arthritis using il-17 antagonists
WO2004013281A2 (en) * 2002-08-05 2004-02-12 Eli Lilly And Company Novel proteins and their uses
AU2003267096B9 (en) * 2002-09-11 2010-11-11 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
JP2009525765A (en) * 2006-02-10 2009-07-16 ザイモジェネティクス， インコーポレイテッド Truncated IL-17RA soluble receptor and method for use in inflammation
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
WO2008067057A2 (en) * 2006-10-13 2008-06-05 The Regents Of The University Of California Cancer treatment
JP5561689B2 (en) * 2007-11-28 2014-07-30 独立行政法人理化学研究所 Screening method for therapeutic agents for allergic airway inflammation and / or airway hypersensitivity using IL-17RB positive NKT cells
CN104628855A (en) 2008-05-05 2015-05-20 诺维莫尼公司 Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
GB0905972D0 (en) 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
JP5743234B2 (en) 2010-01-15 2015-07-01 キリン−アムジェン・インコーポレーテッド Antibody formulations and treatment regimens
SG184195A1 (en) * 2010-03-30 2012-11-29 Janssen Biotech Inc Humanized il-25 antibodies
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014240A1 (en) * 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
WO1999035263A2 (en) * 1998-01-09 1999-07-15 Immunex Corporation Il-17rh dna and polypeptides
WO2000055204A1 (en) * 1999-03-16 2000-09-21 Human Genome Sciences, Inc. Interleukin 17 receptor-like protein
WO2000060080A2 (en) * 1999-04-05 2000-10-12 Incyte Pharmaceuticals, Inc. Molecules of the immune system
WO2001057202A2 (en) * 2000-02-04 2001-08-09 The Board Of Trustees Of The University Of Arkansas Evi27 gene sequences and protein encoded thereby
WO2001059120A2 (en) * 2000-02-08 2001-08-16 Amgen, Inc. Il-17 like molecules and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5319071A (en) 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
DE69233441T2 (en) 1991-04-26 2005-10-13 Osaka Bioscience Institute, Suita Human cell surface antigen encoding DNA
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
CA2161015A1 (en) 1993-05-26 1994-12-08 Tak Wah Mak Transgenic mammals lacking expression of particular cd45 isoforms
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
MX9704780A (en) 1994-12-23 1998-05-31 Uab Research Foundation Secreted human fas antigen.
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
CA2244363C (en) 1996-02-28 2006-11-14 Ariad Gene Therapeutics, Inc. Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains
WO2000042187A1 (en) * 1999-01-11 2000-07-20 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
US9100155B2 (en) 2010-05-03 2015-08-04 Qualcomm Incorporated Method and apparatus for control and data multiplexing in wireless communication
JP6160461B2 (en) 2013-11-29 2017-07-12 富士通株式会社 Likelihood weighting circuit

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014240A1 (en) * 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
WO1999035263A2 (en) * 1998-01-09 1999-07-15 Immunex Corporation Il-17rh dna and polypeptides
WO2000055204A1 (en) * 1999-03-16 2000-09-21 Human Genome Sciences, Inc. Interleukin 17 receptor-like protein
WO2000060080A2 (en) * 1999-04-05 2000-10-12 Incyte Pharmaceuticals, Inc. Molecules of the immune system
WO2001057202A2 (en) * 2000-02-04 2001-08-09 The Board Of Trustees Of The University Of Arkansas Evi27 gene sequences and protein encoded thereby
WO2001059120A2 (en) * 2000-02-08 2001-08-16 Amgen, Inc. Il-17 like molecules and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of EP1265924A2 *
TIAN ERMING ET AL: "Evi27 encodes a novel membrane protein with homology to the IL17 receptor.", ONCOGENE, vol. 19, no. 17, 20 April 2000 (2000-04-20), pages 2098 - 2109, XP008000240, ISSN: 0950-9232 *
YAO Z ET AL: "MOLECULAR CHARACTERIZATION OF THE HUMAN INTERLEUKIN (IL)-17 RECEPTOR", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 9, no. 11, November 1997 (1997-11-01), pages 794 - 800, XP000867704, ISSN: 1043-4666 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9475873B2 (en) 2009-05-05 2016-10-25 Novimmune Sa Nucleic acids encoding anti-IL-17F antibodies and methods of use thereof

Also Published As

Publication number Publication date
CA2401273A1 (en) 2001-09-20
AR030554A1 (en) 2003-08-27
WO2001068705A2 (en) 2001-09-20
MXPA02009024A (en) 2003-02-12
AU5902901A (en) 2001-09-24
AU2001259029B2 (en) 2006-01-05
EP1265924A2 (en) 2002-12-18
JP2003527117A (en) 2003-09-16
TWI322154B (en) 2010-03-21

Similar Documents

Publication Publication Date Title
WO2002008285A3 (en) Il-17 molecules and uses thereof
WO2001068859A3 (en) Il-17 receptor like molecules and uses thereof
WO2001068705A3 (en) Il-17 receptor like molecules and uses thereof
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2002002624A3 (en) B7-like molecules and uses thereof
WO2002024891A3 (en) B7-like molecules and uses thereof
WO2002020762A3 (en) Tnf receptor-like molecules and uses thereof
WO2002000724A3 (en) Thymic stromal lymphopoietin receptor molecules and uses thereof
WO2001070977A3 (en) Fibroblast growth factor receptor-like molecules and uses thereof
WO2001012662A3 (en) Membrane associated proteins
WO2001061007A3 (en) Fibroblast growth factor-23 molecules and uses thereof
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2001042474A3 (en) Interferon-like molecules and uses thereof
WO2002010388A3 (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF
WO2002000723A3 (en) Thymic stromal lymphopoietin receptor molecules and uses thereof
WO2000044900A3 (en) Nucleic-acid binding proteins
WO2001074903A3 (en) Cd20/ige-receptor like molecules and uses thereof
PL374550A1 (en) Il-17 like molecules and uses thereof
WO2001059120A3 (en) Il-17 like molecules and uses thereof
WO2004044165A3 (en) Lipid-associated proteins
WO2002097046A3 (en) B7 related protein-2 molecules and uses thereof
WO2002083736A3 (en) G-protein coupled receptor molecules and uses thereof
WO2002014489A3 (en) Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof
WO2001083524A3 (en) Rna metabolism proteins
WO2002099108A3 (en) Atp-binding cassette transporter-like molecules and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2401273

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001259029

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 567795

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009024

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001932510

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001932510

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001259029

Country of ref document: AU